Skip to Content
Search Menu
Hematology
Welcome to hematology

Find the latest news within hematology here

News from hematology

Florian Simon

EHA 2026: Acalabrutinib Shows Durable Responses in Frail and Elderly Patients with CLL

/ Florian Simon
CLLEHA26 Play the Video
Mattia D' Agostino

ASCO 2026: Sustained MRD and Outcomes in Multiple Myeloma

/ Mattia D' Agostino
ASCO26Multiple myeloma Play the Video

EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL

/ Jan Andreasen
CLLEHA26
Panagiotis Baliakas

EHA 2026: Germline Testing Beyond Family History in AML and MDS

/ Panagiotis Baliakas
EHA26 Play the Video
Mika Kontro

EHA 2026: Novel Cell Therapy Approaches in AML

/ Mika Kontro
AMLEHA26 Play the Video
Mikkel Werling

Machine Learning for Risk Stratification in DLBCL

/ Mikkel Werling
Lymphoma Play the Video
Caroline Arvé

EHA 2026: MRD Predicts Post-Transplant Relapse in High-Risk MDS and AML

/ Caroline Arvé
AMLEHA26 Play the Video
Astrid Hundeboell Torpe

EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma

/ Astrid Hundebøll Torpe
EHA26Myeloma Play the Video
Load more

AML highlights

AML Insights – December Update: What’s New in the Field

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Nordic AML Insights - December Update

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Top Abstract Spotlight: Menin Inhibitors are a Game Changer for the Treatment of Patients with Newly Diagnosed AML 

/ Jan Andreasen
AMLASH25

AML Insights – November Update: What’s New in the Field

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Nordic AML Insights – November Update

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Arsenic Trioxide-Induced Oral Manifestations: A Case of Vallate Papillae Swelling

/ Harisankar Anantharajan / Peter Bjerring / Luit Penninga / Carsten Sauer Mikkelsen
AML
Load more

AML

EHA 2026: Novel Cell Therapy Approaches in AML

/ Hematology / Mika Kontro

EHA 2026: MRD Predicts Post-Transplant Relapse in High-Risk MDS and AML

/ Hematology / Caroline Arvé

AML Insights – December Update: What’s New in the Field

/ Hematology / Amanda Feldballe Bernholm / Jan Andreasen

Nordic AML Insights - December Update

/ Hematology / Amanda Feldballe Bernholm / Jan Andreasen

Top Abstract Spotlight: Menin Inhibitors are a Game Changer for the Treatment of Patients with Newly Diagnosed AML 

/ Hematology / Jan Andreasen
Se oversigt

CLL

EHA 2026: Acalabrutinib Shows Durable Responses in Frail and Elderly Patients with CLL

/ Hematology / Florian Simon

EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL

/ Hematology / Jan Andreasen

EHA 2026: Tacabrutideg Shows High Response Rates and Durable Outcomes in High-Risk Relapsed/Refractory CLL

/ Hematology / Stephan Stilgenbauer

Pirtobrutinib Showed Positive Efficacy and Safety vs Ibrutinib in BTKi-naïve CLL/SLL Patients Both for Treatment-naïve Patients and Patients with R/R Disease

/ Hematology / Wojciech Jurczak

Fixed-Duration Venetoclax Regimens Match Continuous BTKi in Frontline CLL

/ Hematology / Jan Andreasen
Se oversigt
Dr. Lei Fan

EHA 2026: LB2501 Advances In Vivo CAR-T with Single-Infusion Treatment

/ Lei Fan
CAR-TEHA26Lymphoma Play the Video

Hematology • Meet the Experts

Get access

Myelom

EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma

/ Hematology / Astrid Hundebøll Torpe

EHA 2026: Low-Dose Venetoclax Demonstrates Durable Responses in Relapsed/Refractory t(11;14) Multiple Myeloma

/ Hematology / Astrid Hundebøll Torpe

EHA 2026: MRD-Negative Responses And Outcomes After VRD Induction And Transplant In Newly Diagnosed Multiple Myeloma

/ Hematology / Frida Bugge Askeland

EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma

/ Hematology / Sigrun Thorsteinsdottir

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Hematology / Paul G. Richardson / Jan Andreasen
Se oversigt

Lymfom

Machine Learning for Risk Stratification in DLBCL

/ Hematology / Mikkel Werling

EHA 2026: LB2501 Advances In Vivo CAR-T with Single-Infusion Treatment

/ Hematology / Lei Fan

Improving CML Outcomes: Nordic CML Study Group Shares New ASH 2025 Insights

/ Hematology / Henrik Hjorth-Hansen

Danish Study Finds That Variability in Eligibility Criteria Hampers Comparability of Frontline DLBCL Trials

/ Hematology / Jelena Jelicic

EHA 2025: Biomarkers as a Guide in Lymphoma Treatment

/ Hematology / Sirpa Leppä
Se oversigt

Magazine

Oncology / Hematology • No. 19 • 2025

  • PD-L1 Positive Triple-Negative Breast Cancer - Toward a New Standard of Care
  • EGFR-Mutated Lung Cancer – A New Treatment Breakthrough
  • Lymphoma – Tattoo Ink May Increase the Risk
Get access
Maren Poulsgaard Jørgensen

EHA 2026: Increased Risk of Psychotropic Drug Use Observed in Patients with Mastocytosis

/ Maren Poulsgaard Jørgensen
EHA26 Play the Video

Follow news from congresses

Back to top